Last updated: 4 July 2019 at 2:04am EST

John Stuart Patton Net Worth




The estimated Net Worth of John Stuart Patton is at least $2.36 Millón dollars as of 19 August 2014. John Patton owns over 75,000 units of Nektar Therapeutics stock worth over $318,595 and over the last 21 years John sold NKTR stock worth over $2,041,090.

John Patton NKTR stock SEC Form 4 insiders trading

John has made over 15 trades of the Nektar Therapeutics stock since 2007, according to the Form 4 filled with the SEC. Most recently John exercised 75,000 units of NKTR stock worth $153,750 on 19 August 2014.

The largest trade John's ever made was exercising 100,000 units of Nektar Therapeutics stock on 13 September 2013 worth over $39,000. On average, John trades about 8,072 units every 55 days since 2004. As of 19 August 2014 John still owns at least 254,876 units of Nektar Therapeutics stock.

You can see the complete history of John Patton stock trades at the bottom of the page.



What's John Patton's mailing address?

John's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY RD., SUITE 17, SAN DIEGO, CA, 92121.

Insiders trading at Nektar Therapeutics

Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie y John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.



What does Nektar Therapeutics do?

nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.



Complete history of John Patton stock trades at Halozyme Therapeutics y Nektar Therapeutics

Persona
Trans.
Transacción
Precio total
John Stuart Patton
Director
Uso de opción $153,750
19 Aug 2014
John Stuart Patton
Director
Uso de opción $39,000
13 Sep 2013
John Stuart Patton
Director
Venta $135,600
16 Oct 2007
John Stuart Patton
Director
Venta $130,350
9 Oct 2007
John Stuart Patton
Director
Venta $133,500
2 Oct 2007
John Stuart Patton
Director
Venta $134,100
25 Sep 2007
John Stuart Patton
Director
Venta $156,016
18 Sep 2007
John Stuart Patton
Director
Venta $195,600
10 Jul 2007
John Stuart Patton
Director
Venta $73,636
26 Jun 2007
John Stuart Patton
Director
Venta $102,188
26 Jun 2007
John Stuart Patton
Director
Venta $205,000
19 Jun 2007
John Stuart Patton
Director
Venta $201,000
12 Jun 2007
John Stuart Patton
Director
Venta $205,400
29 May 2007
John Stuart Patton
Director
Venta $157,500
23 May 2007
John Stuart Patton
Director
Venta $211,200
22 May 2007


Nektar Therapeutics executives and stock owners

Nektar Therapeutics executives and other stock owners filed with the SEC include: